Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: Clinical significance and options for management

Current Opinion in Infectious Diseases

Volumn 20, Issue 6, 2007, Pages 568-573

  Lewis II, James S ^a,b   Ellis, Michael W ^c  

^a UNIVERSITY HEALTH SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Accessory gene regulator (agr); Methicillin resistant Staphylococcus aureus; Vancomycin intermediate Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; LIPOPEPTIDE; TELAVANCIN; VANCOMYCIN;

AGR GENE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL PNEUMONIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE LOCUS; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 35848961409     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282f1beb8     Document Type: Review

References (55)

1. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 16th informational supplement M100-S16. Wayne, PA: CLSI; 2006.
2. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-439.
3. Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-528.
4. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-1215. An outstanding overview of the data and reasoning for the CLSI's changing of the vancomycin breakpoints for S. aureus.
5. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-2144. The best clinical data available to support the theory that vancomycin MICs of 2.0 μg/ml are problematic.
6. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1089-1091. This study highlights the problems associated with low vancomycin levels and the development of VISA as well as issues with the agr locus.
7. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-1705.
8. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49:2687-2692.
9. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42:s40-s50. An outstanding, in-depth, review of the current knowledge regarding the agr locus and its importance in MRSA.
10. Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 57:699-704.
11. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-1502.
12. Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006; 50:4195-4197.
13. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-665. The first large bacteremia trial completed in years. This study contains the data used to gain daptomycin its current indication.
14. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-1585.
15. Mwangi MM, Wei Wu S, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acac Sci U S A 2007; 104:9451-9456. An in-depth molecular evaluation of sequential changes in one patient's MRSA isolates over time with continued vancomycin exposure. The paper clearly high-lights cross-resistance issues with daptomycyin.
16. Patel JB, Jevitt LA, Hageman J, et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42:1652-1653. This paper highlights the issue of potential cross-resistance between daptomycin and vancomycin.
17. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058-1060.
18. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44:595-597.
19. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-142.
20. Wootton M, Howe RA, Walsh TR, et al. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and hetero VRSA (hVRSA). J Antimicrob Chemother 2002; 50:760-761.
21. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-4219.
22. Bozdogan B, Esel D, Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52:864-868.
23. Meka VG, Howard GS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010-1015.
24. Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27:300-302.
25. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin resistant Staphylococcus aureus in three communities. N Engl J Med 2005; 352:1436-1444.
26. Hageman JC, Pegues DA, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001; 7:1023-1025.
27. Ward PB, Hohnson PD, Brabsch EA, et al. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 2001; 175:480-483.
28. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther 2007; 5:393-401.
29. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-2266.
30. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:940-945.
31. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298-1303.
32. Lin SW, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of Gram-positive infections. Ann Pharmacother 2006; 40:449-460.
33. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48:137-143.
34. Lefort A, Pavie J, Garry L, et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004; 48:1061-1064.
35. Goldstein BP, Draghi DC, Sheehan DJ, et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007; 51:1150-1154.
36. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298-1303.
37. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005; 40:374-380.
38. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-1415.
39. Barcia-Macay M, Lemaire S, Mingeot-Leclercq M, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:1177-1184.
40. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:338-343.
41. Madrigal AG, Basuino Li, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3163-3165.
42. Corey R, Stryjewski M, O'Riordan W, et al. Telavancin for the treatment of complicated skin and skin structure infections (cSSSI): results of the ATLAS I Study. In: Program and Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Canada; 12-15 October 2006. Abstract LB-17.
43. Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin Microbiol Infect 2006; 12 (Suppl. 2):11-16.
44. Jones ME. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13 (Suppl. 2):17-22.
45. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect 2006; 12 (Suppl. 2):17-22.
46. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:884-888.
47. Noel GJ, Strauss RS, Pypstra R, et al. Successful treatment of complicated skin infections due to Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus with ceftobiprole. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; 27-30 September 2006. Abstract L1212.
48. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25:253-264.
49. Drew RH. Emerging options for treatment of invasive multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27:227-249.
50. Graber CJ, Wong MK, Carleton HA, et al. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 2007; 13:491-493.
51. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-1347.
52. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51:231-238.
53. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340:493-501.
54. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-398.
55. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-1406.